Analysis of Tim-3 as a therapeutic target in prostate cancer
Tim-3 (T-cell immunoglobulin domain and mucin domain–containing molecule 3) is a newly discovered immunomodulatory protein, which plays an important role in immunity regulation. Recent evidence suggests that Tim-3 is differentially regulated in a variety of tumors and has potential as a therapeutic...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2017-07-01
|
| Series: | Tumor Biology |
| Online Access: | https://doi.org/10.1177/1010428317716628 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849687206658048000 |
|---|---|
| author | Yongrui Piao Xuanshun Jin |
| author_facet | Yongrui Piao Xuanshun Jin |
| author_sort | Yongrui Piao |
| collection | DOAJ |
| description | Tim-3 (T-cell immunoglobulin domain and mucin domain–containing molecule 3) is a newly discovered immunomodulatory protein, which plays an important role in immunity regulation. Recent evidence suggests that Tim-3 is differentially regulated in a variety of tumors and has potential as a therapeutic target. The aim of this study was to investigate the effect of Tim-3 on the development of prostate cancer. Tim-3 expressing on peripheral CD4+ T and CD8+ T cells was analyzed by flow cytometry. The relationships between Tim-3 expression and clinicopathological features were analyzed. Immunohistochemical expression of Tim-3 was examined in our large numbers of paraffin-fixed prostate tissues. Flow cytometry revealed that expression of Tim-3 was significantly increased on both CD4+ and CD8+ T cells in prostate cancer patients than that in benign prostate hyperplasia patients. Also, the level of Tim-3 on CD4+ T cells was positively correlated with CD8+ T cells in patients. Further analyses revealed that the levels of Tim-3 on CD4+ T cells and CD8+ T cells exhibited different expression patterns in terms of localization depending on pathological category of prostate cancer and metastasis. Immunohistochemical analysis revealed that positive staining of Tim-3 in prostate cancer but little or no staining of Tim-3 was observed in benign prostate hyperplasia epithelium. Tim-3 may affect the development and progression of prostate cancer, which may provide knowledge for using Tim-3 as a novel therapy for effective prostate cancer management. |
| format | Article |
| id | doaj-art-fb6c4e61319047b988b07832b4342adc |
| institution | DOAJ |
| issn | 1423-0380 |
| language | English |
| publishDate | 2017-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Tumor Biology |
| spelling | doaj-art-fb6c4e61319047b988b07832b4342adc2025-08-20T03:22:22ZengSAGE PublishingTumor Biology1423-03802017-07-013910.1177/1010428317716628Analysis of Tim-3 as a therapeutic target in prostate cancerYongrui Piao0Xuanshun Jin1Department of Urology, Affiliated Hospital of Yanbian University, Yanji, ChinaDepartment of Cardiology, Affiliated Hospital of Yanbian University, Yanji, ChinaTim-3 (T-cell immunoglobulin domain and mucin domain–containing molecule 3) is a newly discovered immunomodulatory protein, which plays an important role in immunity regulation. Recent evidence suggests that Tim-3 is differentially regulated in a variety of tumors and has potential as a therapeutic target. The aim of this study was to investigate the effect of Tim-3 on the development of prostate cancer. Tim-3 expressing on peripheral CD4+ T and CD8+ T cells was analyzed by flow cytometry. The relationships between Tim-3 expression and clinicopathological features were analyzed. Immunohistochemical expression of Tim-3 was examined in our large numbers of paraffin-fixed prostate tissues. Flow cytometry revealed that expression of Tim-3 was significantly increased on both CD4+ and CD8+ T cells in prostate cancer patients than that in benign prostate hyperplasia patients. Also, the level of Tim-3 on CD4+ T cells was positively correlated with CD8+ T cells in patients. Further analyses revealed that the levels of Tim-3 on CD4+ T cells and CD8+ T cells exhibited different expression patterns in terms of localization depending on pathological category of prostate cancer and metastasis. Immunohistochemical analysis revealed that positive staining of Tim-3 in prostate cancer but little or no staining of Tim-3 was observed in benign prostate hyperplasia epithelium. Tim-3 may affect the development and progression of prostate cancer, which may provide knowledge for using Tim-3 as a novel therapy for effective prostate cancer management.https://doi.org/10.1177/1010428317716628 |
| spellingShingle | Yongrui Piao Xuanshun Jin Analysis of Tim-3 as a therapeutic target in prostate cancer Tumor Biology |
| title | Analysis of Tim-3 as a therapeutic target in prostate cancer |
| title_full | Analysis of Tim-3 as a therapeutic target in prostate cancer |
| title_fullStr | Analysis of Tim-3 as a therapeutic target in prostate cancer |
| title_full_unstemmed | Analysis of Tim-3 as a therapeutic target in prostate cancer |
| title_short | Analysis of Tim-3 as a therapeutic target in prostate cancer |
| title_sort | analysis of tim 3 as a therapeutic target in prostate cancer |
| url | https://doi.org/10.1177/1010428317716628 |
| work_keys_str_mv | AT yongruipiao analysisoftim3asatherapeutictargetinprostatecancer AT xuanshunjin analysisoftim3asatherapeutictargetinprostatecancer |